This is a prospective study of patients receiving radiotherapy or chemoradiotherapy for anal cancer. Treatment effect in terms of survival and local recurrence will be analyzed. The utility of PET-CT and MRI for radiotherapy and for prediction of treatment effect will be investigated. Molecular and genetic markers in tumor and blood will be analyzed for prognostic and predictive effects. Patient-reported outcomes, such as faecal incontinence, sexual dysfunction and quality of life will be assessed. A structured intervention program for management of late effects will be evaluated. Symptom relief of palliative radiotherapy will be investigated. The main purpose of the study is to increase the knowledge of anal cancer treatment, improve treatment results, and improve anal cancer survivor care.
Study Type
OBSERVATIONAL
Enrollment
75
Oslo University Hospital
Oslo, Norway
Disease-free survival
Time frame: 3 years
Prediction of local recurrence
Time frame: 2 years
Biomarker ability to predict local recurrence rate
Substudy will analyze biomarkers in tissue/blood that may predict poor radiotherapy response or local recurrence.
Time frame: 5 years
Improvement of faecal incontinence
Time frame: 5 years
Pain relief of palliative radiotherapy
Substudy will prospectively evaluate relief of pain and other symptoms of anal cancer after completion of palliative radiotherapy.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.